Literature DB >> 33942212

Subcutaneous Injection Site Pain of Formulation Matrices.

Galen H Shi1, Karthik Pisupati1, Jonathan G Parker1, Vincent J Corvari2, Christopher D Payne1, Wen Xu1, David S Collins1, Michael R De Felippis1.   

Abstract

PURPOSE: The objective of this work was to systematically evaluate the effects of formulation composition on subcutaneous injection site pain (ISP) using matrices comprising of common pharmaceutical excipients.
METHODS: Two randomized, blinded, crossover studies in healthy subjects were conducted at a single site, where subjects received 1 mL SC injections of the buffer matrices. ISP intensity was measured using a 100 mm visual analogue scale (VAS), which was then analyzed via heatmap, categorical grouping, subgroup analysis, and paired delta analysis.
RESULTS: Buffer type, buffer concentration and tonicity agent showed a substantial impact on ISP. Citrate buffer demonstrated a higher ISP than acetate buffer or saline). The 20 mM citrate buffer was more painful than 10 or 5 mM citrate buffers. NaCl and propylene glycol were significantly more painful than sugar alcohols (mannitol, sucrose, trehalose or glycerol). Histidine buffers exhibited ISP in the descending order of 150 mM > 75 mM > 25 mM > 0 mM NaCl, while histidine buffers containing Arginine-HCl at 0, 50, or 150 mM all showed very low ISP. Histidine buffer at pH 6.5 showed a lower ISP than pH 5.7.
CONCLUSIONS: This systematic study via orthogonal analyses demonstrated that subcutaneous ISP is significantly influenced by solution composition.

Entities:  

Keywords:  buffer solution; formulation; injection pain; visual analog scale

Year:  2021        PMID: 33942212     DOI: 10.1007/s11095-021-03047-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

Review 1.  Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics.

Authors:  David S Collins; Manuel Sánchez-Félix; Advait V Badkar; Randall Mrsny
Journal:  J Control Release       Date:  2020-02-24       Impact factor: 9.776

2.  Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Authors:  Saad Z Usmani; Hareth Nahi; Maria-Victoria Mateos; Niels W C J van de Donk; Ajai Chari; Jonathan L Kaufman; Philippe Moreau; Albert Oriol; Torben Plesner; Lotfi Benboubker; Peter Hellemans; Tara Masterson; Pamela L Clemens; Man Luo; Kevin Liu; Jesus San-Miguel
Journal:  Blood       Date:  2019-07-03       Impact factor: 22.113

3.  Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.

Authors:  C Victor Spain; Jonathon J Wright; Rebecca M Hahn; Ashley Wivel; Alan A Martin
Journal:  Clin Ther       Date:  2016-06-28       Impact factor: 3.393

Review 4.  Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Michael R Turner; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-01-11       Impact factor: 3.534

5.  Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Authors:  A Martin; L Lavoie; M Goetghebeur; R Schellenberg
Journal:  Transfus Med       Date:  2012-11-20       Impact factor: 2.057

Review 6.  The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.

Authors:  Andrea Matucci; Alessandra Vultaggio; Romano Danesi
Journal:  Respir Res       Date:  2018-08-16

7.  Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.

Authors:  Elham Hedayati; Lionel Fracheboud; Vaidyanathan Srikant; David Greber; Susanne Wallberg; Christina Linder Stragliotto
Journal:  PLoS One       Date:  2019-02-04       Impact factor: 3.240

8.  Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old.

Authors:  David L Gandell; E Jay Bienen; Jennifer Gudeman
Journal:  Patient Prefer Adherence       Date:  2019-02-22       Impact factor: 2.711

9.  The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

Authors:  K Papadmitriou; X B Trinh; S Altintas; P A Van Dam; M T Huizing; W A A Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2015

Review 10.  Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.

Authors:  Beate Bittner; Wolfgang Richter; Johannes Schmidt
Journal:  BioDrugs       Date:  2018-10       Impact factor: 5.807

View more
  5 in total

1.  Impact of IgG subclass on molecular properties of monoclonal antibodies.

Authors:  Yu Tang; Paul Cain; Victor Anguiano; James J Shih; Qing Chai; Yiqing Feng
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

2.  Development of an Insulin Pen is a Patient-Centric Multidisciplinary Undertaking: A Commentary.

Authors:  Thomas Sparre; Niels-Aage B Hansen; Anya Sonia Wernersson; Mark Guarraia
Journal:  J Diabetes Sci Technol       Date:  2021-12-01

3.  Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Authors:  Viktoria Bergqvist; Johanna Holmgren; Daniel Klintman; Jan Marsal
Journal:  Aliment Pharmacol Ther       Date:  2022-04-25       Impact factor: 9.524

4.  Ionic Liquid-Based Strategy for Predicting Protein Aggregation Propensity and Thermodynamic Stability.

Authors:  Talia A Shmool; Laura K Martin; Richard P Matthews; Jason P Hallett
Journal:  JACS Au       Date:  2022-09-09

Review 5.  New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain.

Authors:  Bita Taghizadeh; Mahmoud Reza Jaafari; Nosratollah Zarghami
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-03       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.